MX2009004861A - Forma de dosificacion farmaceutica para la administracion oral de inhibidor de tirosina quinasa. - Google Patents

Forma de dosificacion farmaceutica para la administracion oral de inhibidor de tirosina quinasa.

Info

Publication number
MX2009004861A
MX2009004861A MX2009004861A MX2009004861A MX2009004861A MX 2009004861 A MX2009004861 A MX 2009004861A MX 2009004861 A MX2009004861 A MX 2009004861A MX 2009004861 A MX2009004861 A MX 2009004861A MX 2009004861 A MX2009004861 A MX 2009004861A
Authority
MX
Mexico
Prior art keywords
dosage form
tyrosine kinase
kinase inhibitor
pharmaceutical dosage
oral administration
Prior art date
Application number
MX2009004861A
Other languages
English (en)
Inventor
Joerg Rosenberg
Bernd Liepold
Martin Knobloch
Christian Nehen
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06023367A external-priority patent/EP1920767A1/en
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of MX2009004861A publication Critical patent/MX2009004861A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

Se presenta una forma de dosificación farmacéutica que comprende un producto de dispersión de sólidos de por lo menos un inhibidor de tirosina quinasa, por lo menos un polímero farmacéuticamente aceptable, y por lo menos un solubilizador farmacéuticamente aceptable.
MX2009004861A 2006-11-09 2007-11-08 Forma de dosificacion farmaceutica para la administracion oral de inhibidor de tirosina quinasa. MX2009004861A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06023367A EP1920767A1 (en) 2006-11-09 2006-11-09 Melt-processed imatinib dosage form
US99957907P 2007-10-19 2007-10-19
PCT/EP2007/062101 WO2008055966A1 (en) 2006-11-09 2007-11-08 Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor

Publications (1)

Publication Number Publication Date
MX2009004861A true MX2009004861A (es) 2009-05-21

Family

ID=38859725

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004861A MX2009004861A (es) 2006-11-09 2007-11-08 Forma de dosificacion farmaceutica para la administracion oral de inhibidor de tirosina quinasa.

Country Status (8)

Country Link
US (1) US20100143459A1 (es)
EP (1) EP2089003A1 (es)
JP (1) JP2010509289A (es)
KR (1) KR20090094815A (es)
AU (1) AU2007316558A1 (es)
CA (1) CA2667720A1 (es)
MX (1) MX2009004861A (es)
WO (1) WO2008055966A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2298311B1 (en) 1999-01-13 2012-05-09 Bayer HealthCare LLC w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
MXPA04007832A (es) 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aril-ureas con actividad inhibitoria de angiogenesis.
CA2526617C (en) 2003-05-20 2015-04-28 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
UA84156C2 (ru) 2003-07-23 2008-09-25 Байер Фармасьютикалс Корпорейшн Фторозамещённая омега-карбоксиарилдифенилмочевина для лечения и профилактики болезней и состояний
US7772404B2 (en) * 2007-10-19 2010-08-10 Abbott Laboratories Crystalline form 2 of the chemotherapeutic N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N′-(2-fluoro-5-methylphenyl)urea
CA2699301A1 (en) * 2007-10-19 2009-04-23 Abbott Gmbh & Co. Kg Solid dispersion product of n-aryl urea-based drugs
US7943782B2 (en) * 2007-10-19 2011-05-17 Abbott Laboratories Crystalline chemotherapeutic
US7947843B2 (en) * 2007-10-19 2011-05-24 Abbott Laboratories Crystalline chemotherapeutic
US7960564B2 (en) * 2007-10-19 2011-06-14 Abbott Laboratories Crystalline chemotherapeutic
US7994208B2 (en) * 2007-10-19 2011-08-09 Abbott Laboratories Crystalline chemotherapeutic
US20090203709A1 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
EP2300825A4 (en) * 2008-06-18 2012-04-25 Abbott Lab P / GF 1 COMPARATIVE DIAGNOSTIC PROCEDURES AND PRODUCTS
BRPI1013366A2 (pt) * 2009-03-06 2016-03-29 Novartis Ag uso de derivados de pirimidilaminobenzamida para o tratamento de distúrbios mediados pela quinase contendo zíper de leucina e quinase contendo motivo alfa estéril (zak).
EP2255792A1 (en) * 2009-05-20 2010-12-01 Ratiopharm GmbH Pharmaceutical compositions for N-[2-(Diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1H-pyrrole-3-carboxamide
WO2011035540A1 (zh) 2009-09-28 2011-03-31 齐鲁制药有限公司 作为酪氨酸激酶抑制剂的4-（取代苯胺基）喹唑啉衍生物
SG186248A1 (en) * 2010-06-09 2013-01-30 Abbvie Inc Solid dispersions containing kinase inhibitors
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
AR086913A1 (es) * 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
CN103764676A (zh) * 2011-08-04 2014-04-30 日本国立癌症研究中心 Kif5b基因和ret基因的融合基因、以及以该融合基因为目标的判断癌症治疗有效性的方法
AU2013208323B2 (en) * 2012-01-13 2017-07-06 Xspray Microparticles Ab A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix- forming component.
DK2802314T3 (da) * 2012-01-13 2021-01-25 Xspray Microparticles Ab Fremgangsmåde til fremstilling af stabile, amorfe hybride nanopartikler, der omfatter mindst én proteinkinaseinhibitor og mindst én polymer stabiliserende og matrixdannende bestanddel
KR101386697B1 (ko) 2012-06-18 2014-04-18 아주대학교산학협력단 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물
KR101674457B1 (ko) * 2013-11-04 2016-11-09 아주대학교산학협력단 다사티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 예방 또는 치료용 약학적 조성물
KR101796684B1 (ko) * 2016-05-19 2017-11-10 건국대학교 산학협력단 케라틴 8 인산화 억제제를 포함하는 황반변성 예방 또는 치료용 약학 조성물 및 황반변성 치료제의 스크리닝 방법
MA47798A (fr) 2017-03-15 2020-01-22 Sun Pharma Advanced Res Co Ltd Nouvelle dispersion amorphe d'acide cyclopropanecarboxylique (5-{5-[ n'-(2-chloro-6-méthylbenzoyl) hydrazinocarbonyl] -2-méthyl-phényléthynyl}-pyridin-2-yl) amide
CA3056348A1 (en) * 2017-03-15 2018-09-20 Sun Pharma Advanced Research Company Limited Novel amorphous dispersion of 4-methyl-3-quinolin-3-ylethynyl-benzoic acid n'-(2-chloro-6-methyl-benzoyl) hydrazide
KR102184117B1 (ko) * 2017-10-31 2020-11-30 주식회사 삼양바이오팜 수용해도 및 생체이용율이 개선된 소라페닙 나노입자 경구용 조성물 및 이의 제조 방법
EP3806858A4 (en) * 2018-06-15 2022-03-09 Handa Pharmaceuticals, Inc. SALTS OF KINASE INHIBITORS AND ASSOCIATED COMPOSITIONS
CN110801434A (zh) * 2019-10-31 2020-02-18 金华职业技术学院 一种冻干法制备甲苯磺酸拉帕替尼固体分散体的方法
KR102538075B1 (ko) * 2019-12-17 2023-05-30 주식회사 삼양홀딩스 수니티닙 염산염을 포함하는 경구용 고형제제 및 그 제조 방법
EP4093379A1 (en) 2020-01-24 2022-11-30 Nanocopoeia LLC Amorphous solid dispersions of dasatinib and uses thereof
JP2023513045A (ja) 2020-01-31 2023-03-30 ナノコピーア リミテッド ライアビリティ カンパニー 非晶質ニロチニブ微粒子及びその使用
WO2021222739A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
CN113876715B (zh) * 2021-10-28 2023-11-21 和记黄埔医药（苏州）有限公司 一种索凡替尼固体分散体及其片剂以及它们的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB0317663D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Pharmaceutical composition
WO2005063209A1 (en) * 2003-12-23 2005-07-14 Tibotec Pharmaceuticals Ltd. Self-microemulsifying drug delivery systems of a hiv protease inhibitor
EP1796642B1 (en) * 2004-08-27 2008-05-21 Bayer Pharmaceuticals Corporation Pharmaceutical compositions in the form of solid dispersions for the treatment of cancer
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
CA2578356C (en) * 2004-09-24 2013-05-28 Boehringer Ingelheim Pharmaceuticals, Inc. A new class of surfactant-like materials
US7625911B2 (en) * 2005-01-12 2009-12-01 Mai De Ltd. Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion
AR052660A1 (es) * 2005-01-21 2007-03-28 Astex Therapeutics Ltd Derivados de pirazol para inhibir la cdk's y gsk's
WO2006081985A1 (en) * 2005-02-04 2006-08-10 F. Hoffmann-La Roche Ag Combined treatment with an n4-(substituted-oxycarbonyl)-5’-deoxy-5-fluorocytidine derivative and an epidermal growth factor receptor kinase inhibitor
CN1857204A (zh) * 2006-03-06 2006-11-08 济南帅华医药科技有限公司 一种同载血管抑制剂及其增效剂的抗癌缓释剂

Also Published As

Publication number Publication date
CA2667720A1 (en) 2008-05-15
AU2007316558A1 (en) 2008-05-15
KR20090094815A (ko) 2009-09-08
EP2089003A1 (en) 2009-08-19
WO2008055966A1 (en) 2008-05-15
US20100143459A1 (en) 2010-06-10
JP2010509289A (ja) 2010-03-25

Similar Documents

Publication Publication Date Title
MX2009004861A (es) Forma de dosificacion farmaceutica para la administracion oral de inhibidor de tirosina quinasa.
WO2009100176A3 (en) Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
ZA200903929B (en) Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
AU2008347158A8 (en) Oral pharmaceutical dosage forms
GB0618879D0 (en) Pharmaceutical compositions
MX2020011961A (es) Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas.
MX343358B (es) Tabletas de acetato de ulipristal.
WO2008146178A3 (en) A novel tablet dosage form
SG10201407947WA (en) Compressible-coated pharmaceutical compositions and tablets and methods of manufacture
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
RS20060140A (en) Solid pharmaceutical dosage form
SI1830855T1 (sl) Trdne oralno aplikabilne farmacevtske dajalne oblike z modificiranim sproščanjem ki vsebujejo rivaroksaban
TN2011000651A1 (en) Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine their preparation and their therapeutic application
WO2007144169A3 (en) Entacapone-derivatives
TW200700062A (en) Pharmaceutical compositions
WO2006076097A3 (en) Stable non-crystalline formulation comprising losartan
ATE479427T1 (de) Pharmazeutische zusammensetzung mit candesartan- cilexetil
WO2010079433A3 (en) Pharmaceutical composition comprising melogliptin
WO2008009802A3 (fr) Medicaments comprenant un inhibiteur des alpha-mannosidases de classe i pour le traitement des sarcoglycanopathies
MA31227B1 (fr) Composition pharmaceutique renfermant du phloroglucinol et du paracetamol.
GB0001315D0 (en) Organic compounds
MX2008010233A (es) Composicion de liberacion modificada, que comprende doxofilina.
GEP20135792B (en) Pharmaceutical compositions based on kinin b2 receptor antagonists and corticosteroids, and use of the same
RS20050866A (en) Controlled release pharmaceutical composition comprising an acid- insoluble and a bioadhesive polymer
PT1499278E (pt) Forma de dosagem farmaceutica de libertacao imediata compreendendo tibolona polimorfa

Legal Events

Date Code Title Description
FA Abandonment or withdrawal